The Lawsuits Threatening the $50B Weight-Loss Drug Empire

The quiet claim that could unsettle a $50 billion market

A wave of lawsuits filed by hundreds of consumers is challenging the safety narrative around the world’s most popular weight-loss and diabetes drugs. The allegation: GLP-1 receptor agonists from Novo Nordisk and Eli Lilly may cause NAION, a rare condition known as an eye stroke that can lead to permanent, untreatable vision loss. The companies deny the link. The science is still inconclusive. But the lawsuits alone are enough to send a tremor through a market that has grown so large it now commands the attention of courts, regulators, and investors worldwide.

What the drugs are accused of doing

NAION — nonarteritic anterior ischemic optic neuropathy — occurs when blood flow to the optic nerve drops suddenly, often waking patients with painless vision loss in one eye. It is the most common cause of acute optic nerve injury in adults over 50. There is no treatment. Vision may partially return, but the nerve damage is typically permanent.

Patients behind the lawsuits say their NAION followed treatment with semaglutide-based drugs — Ozempic and Wegovy from Novo Nordisk, and Tirzepatide-based Mounjaro and Zepbound from Eli Lilly. Both companies have pushed back. Novo Nordisk called the claims meritless, pointing to its own research finding no increased NAION risk. Eli Lilly said it continues to monitor safety data and that current studies do not establish causation.

What the data actually says

The research base is thin and uneven. Most published studies examine semaglutide, not tirzepatide. A 2025 analysis of 37 million adults in JAMA Ophthalmology found a modest increase in NAION risk among semaglutide users compared to those on SGLT2 inhibitors, another diabetes drug class. A 2024 Harvard Medical School study found roughly a fourfold higher relative risk, though the absolute risk remained very low.

Both studies were observational. Neither can prove the drugs caused NAION. That distinction matters enormously in court, where causation is the central question — and where lawyers will press hard on whether diabetes and obesity themselves, not the medication, explain the vision loss.

The regulatory split is telling

The FDA is reviewing available evidence and has not concluded that semaglutide causes NAION. It has not issued a safety warning. The European Medicines Agency has gone further, concluding there is sufficient evidence of a possible association to recommend adding NAION as a very rare adverse reaction to product information in Europe. The divergence signals something important: regulators are not yet aligned, and the legal exposure for manufacturers remains open-ended.

Who this really hits

Novo Nordisk and Eli Lilly dominate the GLP-1 space. Their combined market value reflects the assumption that demand will keep climbing and that safety surprises will stay manageable. Lawsuits change the calculus. Even if the plaintiffs lose on causation, the cost of defense, the distraction from leadership, and the risk of precedent all weigh on valuation. A single verdict or settlement that acknowledges the link could trigger thousands more claims — and potentially class-action consolidation.

The numbers behind NAION make this complicated, not simple. The condition affects roughly two to 10 people per 100,000 annually. Millions of patients are on GLP-1 drugs globally. Even a small relative risk increase, applied across that population, produces real-world cases. That is the math driving the litigation.

The confounding problem

Diabetes is a well-established risk factor for NAION. So is high blood pressure, high cholesterol, obstructive sleep apnea, smoking, and age over 50. The very patients most likely to be prescribed semaglutide carry many of those risks. disentangling the drug from the disease is notoriously difficult in observational research, and it is the same difficulty that will haunt every plaintiff expert and every defense expert in depositions.

Dr. Douglas Lazzaro, an ophthalmologist at NYU Langone Health, noted that when researchers removed confounding variables, a higher risk of NAION did emerge. But he also stressed that statistical significance is hard to pin down given the number of variables involved. His clinical takeaway is direct: patients with a crowded optic disc anatomy — what doctors call a disc at risk — should probably avoid semaglutide. For everyone else, he said, the health benefits likely outweigh the risks.

What happens next

A few paths are plausible. The most likely: prolonged litigation with scattered settlements, no sweeping precedent, and continued regulatory ambiguity. The FDA may eventually issue a warning label if new data accumulates, but that does not guarantee liability for manufacturers. The second path: a handful of high-profile cases produce verdicts or settlements that shift the market’s risk perception, even without a definitive scientific answer. The third, least likely but most disruptive: multidistrict litigation consolidation, a landmark case, and a ruling that forces a re-evaluation of prescribing guidelines globally.

Investors should watch three signals. First, whether the FDA moves from review to a formal safety communication. Second, whether the EMA’s recommendation triggers labeling changes that other regulators follow. Third, the volume and velocity of new filings — hundreds is the current count, but the number could accelerate quickly if early plaintiffs share success stories.

Why this matters beyond the courtroom

The GLP-1 market is not just a pharma story. It is a consumer health story, a workforce productivity story, and a healthcare-cost story. Novo Nordisk and Eli Lilly built their growth projections on the assumption that these drugs are safe enough for long-term use across millions of people. A credible vision-loss claim undermines that assumption, even before any verdict is reached. The market prices certainty. Uncertainty is expensive.

For patients, the message from experts is consistent: do not stop taking prescribed GLP-1 medications without consulting a doctor. The proven benefits for diabetes and weight management are substantial. But the lawsuits ensure that the conversation about risk will no longer be confined to medical journals. It will play out in courtrooms, in prescribing decisions, and in the quarterly reports of two of the world’s most valuable pharmaceutical companies.